Economic impact of contrast-induced acute kidney injury associated with invasive cardiology: role of iso-osmolar contrast media in Germany, Italy, Poland, and Spain

被引:5
作者
De Francesco, Maria [1 ]
Ronco, Claudio [2 ]
Wacinski, Piotr J. [3 ]
Wessely, Rainer [4 ]
Hernandez, Felipe [5 ]
Lamotte, Mark [1 ]
机构
[1] IMS Hlth, Vilvoorde, Belgium
[2] San Bortolo Hosp, Vicenza, Italy
[3] Med Univ Lublin, Lublin, Poland
[4] Zentrum Herz Gefass & Lungenmed, Cologne, Germany
[5] Hosp Univ Doce Octubre, Madrid, Spain
关键词
Budget impact; Contrast media; Acute kidney injury; Iodixanol; RISK; INTRAARTERIAL; OUTCOMES;
D O I
10.3111/13696998.2015.1105809
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: Iso-osmolar Iodixanol is associated with a lower rate of contrast-induced acute kidney injury (CI-AKI) in patients at increased risk compared to low-osmolar contrast media (LOCM). The aim of this study was to assess the financial consequences of CI-AKI risk reduction in patients undergoing coronary angiography (CA) with or without percutaneous coronary intervention (PCI) in German, Italian, Polish and Spanish hospitals. Methods: This budget impact analysis (BIA) compared a scenario with iodixanol to a scenario without, where only LOCM were used, in patients at increased risk of CI-AKI over a 3-year horizon. A meta-analysis based on a systematic review observed a lower rate of CI-AKI with iodixanol compared to LOCM (Risk Reduction=0.46) in patients with underlying impaired renal function (serum creatinine >= 1.6mg/dl and estimated glomerular filtration rate <= 50ml/min/1.73 m(2)). Contrast media and CI-AKI hospitalization costs were included in the analysis and unit costs were obtained from published literature, official sources or, when available, from hospital data. In the absence of country-specific data, resource utilization for a CI-AKI hospitalization was obtained by interviews with local clinicians in each country. The percentage of patients who received iodixanol was assumed to increase over time. Results: Based on a percentage of patients at increased risk of CI-AKI equal to 20% in Germany, 24% in Italy, 23% in Poland and 10% in Spain, results showed that the introduction of iodixanol would bring a 3-years cumulative net percentage saving on the total hospital budget of 29%, 34%, 25%, and 33% in the four countries respectively. Conclusion: The results of the analysis for the four countries showed that iodixanol use in patients at increased risk of CI-AKI undergoing CA with or without PCI may bring considerable savings on the hospital's budget, due to the associated reduction in CI-AKI incidence.
引用
收藏
页码:158 / 168
页数:11
相关论文
共 20 条
[1]  
[Anonymous], 2017, SURV REP EXC REV 201
[2]  
[Anonymous], 2013, Kidney Int Suppl, DOI [10.1038/kisup.2012.73, DOI 10.1038/KISUP.2012.73]
[3]   Nephrotoxic effects in high-risk patients undergoing angiography. [J].
Aspelin, P ;
Aubry, P ;
Fransson, S ;
Strasser, R ;
Willenbrock, R ;
Berg, KJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :491-499
[4]  
Busse R., 2011, Diagnosis-Related Groups in Europe
[5]   The severity of acute kidney injury predicts progression to chronic kidney disease [J].
Chawla, Lakhmir S. ;
Amdur, Richard L. ;
Amodeo, Susan ;
Kimmel, Paul L. ;
Palant, Carlos E. .
KIDNEY INTERNATIONAL, 2011, 79 (12) :1361-1369
[6]  
Colombo GL, 2013, PHARMACOECONOMICS IT, V7, P145
[7]   Effect of administration route on the renal safety of contrast agents: a meta-analysis of randomized controlled trials [J].
Dong, Mei ;
Jiao, Zhanquan ;
Liu, Tong ;
Guo, Fangming ;
Li, Guangping .
JOURNAL OF NEPHROLOGY, 2012, 25 (03) :290-301
[8]   A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy [J].
Fliser, Danilo ;
Laville, Maurice ;
Covic, Adrian ;
Fouque, Denis ;
Vanholder, Raymond ;
Juillard, Laurent ;
Van Biesen, Wim .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (12) :4263-4272
[9]  
GE Healthcare, 2013, DRUG PRIC MARK SHAR
[10]  
GE Healthcare, 2014, DRUG PRIC